Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy

被引:24
作者
Lamarca, Angela [1 ]
Rigby, Christina [1 ]
McNamara, Mairead G. [1 ,2 ]
Hubner, Richard A. [1 ]
Valle, Juan W. [1 ,2 ]
机构
[1] Christie NHS Fdn Trust, Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Univ Manchester, Inst Canc Sci, Manchester Acad Hlth Sci Ctr, Manchester M20 4BX, Lancs, England
关键词
Advanced biliary tract cancer; Pancreatic cancer; Biliary obstruction; Biliary stent; Stent-related event; BILE-DUCT STONES; URSODEOXYCHOLIC ACID; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; PREVENTION; OCCLUSION; CIPROFLOXACIN; OBSTRUCTION; CANCER; MULTICENTER;
D O I
10.3748/wjg.v22.i26.6065
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: to determine the impact (morbidity/mortality) of biliary stent-related events (SRE) (cholangitis or stent obstruction) in chemotherapy-treated pancreaticobiliary patients. METHODS: All consecutive patients with advanced pancreatobiliary cancer and a biliary stent in-situ prior to starting palliative chemotherapy were identified retrospectively from local electronic case-note records (Jan 13 to Jan 15). The primary end-point was SRE rate and the time-to-SRE (defined as time from first stenting before chemotherapy to date of SRE). Progression-free survival and overall survival were measured from the time of starting chemotherapy. Kaplan-Meier, Cox and Fine-Gray regression (univariate and multivariable) analyses were employed, as appropriate. For the analysis of time-to-SRE, death was considered as a competing event. RESULTS: Ninety-six out of 693 screened patients were eligible; 89% had a metal stent (the remainder were plastic). The median time of follow-up was 9.6 mo (range 2.2 to 26.4). Forty-one patients (43%) developed a SRE during follow-up [cholangitis (39%), stent obstruction (29%), both (32%)]. There were no significant differences in baseline characteristics between the SRE group and no-SRE groups. Recorded SRE-consequences were: none (37%), chemotherapy delay (24%), discontinuation (17%) and death (22%). The median time-to-SRE was 4.4 mo (95% CI: 3.6-5.5). Patients with severe comorbidities (p < 0.001) and patients with >= 2 baseline stents/biliary procedures [HR = 2.3 (95% CI: 1.2-4.44), p = 0.010] had a shorter time-to-SRE on multivariable analysis. Stage was an independent prognostic factor for overall survival (p = 0.029) in the multivariable analysis adjusted for primary tumour site, performance status and development of SRE (SRE group vs no-SRE group). CONCLUSION: SREs are common and impact on patient's morbidity. Our results highlight the need for prospective studies exploring the role of prophylactic strategies to prevent/delay SREs.
引用
收藏
页码:6065 / 6075
页数:11
相关论文
共 32 条
  • [1] SYMPTOM RELIEF AND QUALITY-OF-LIFE AFTER STENTING FOR MALIGNANT BILE-DUCT OBSTRUCTION
    BALLINGER, AB
    MCHUGH, M
    CATNACH, SM
    ALSTEAD, EM
    CLARK, ML
    [J]. GUT, 1994, 35 (04) : 467 - 470
  • [2] RANDOMIZED TRIAL OF PREVENTION OF BILIARY STENT OCCLUSION BY URSODEOXYCHOLIC ACID PLUS NORFLOXACIN
    BARRIOZ, T
    INGRAND, P
    BESSON, I
    DELEDINGHEN, V
    SILVAIN, C
    BEAUCHANT, M
    [J]. LANCET, 1994, 344 (8922) : 581 - 582
  • [3] Managing malignant biliary obstruction in pancreas cancer: Choosing the appropriate strategy
    Boulay, Brian R.
    Parepally, Mayur
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (28) : 9345 - 9353
  • [4] The role of ciprofloxacin in prolonging polyethylene biliary stent patency: A MultiCenter, double-blinded effectiveness study
    Chan, G
    Barkun, JE
    Barkun, AN
    Valois, E
    Cohen, A
    Friedman, G
    Parent, J
    Love, YJ
    Enns, R
    Baffis, V
    Jabbari, M
    Szego, P
    Stein, L
    Abraham, N
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2005, 9 (04) : 481 - 488
  • [5] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
    Conroy, Thierry
    Desseigne, Francoise
    Ychou, Marc
    Bouche, Olivier
    Guimbaud, Rosine
    Becouarn, Yves
    Adenis, Antoine
    Raoul, Jean-Luc
    Gourgou-Bourgade, Sophie
    de la Fouchardiere, Christelle
    Bennouna, Jaafar
    Bachet, Jean-Baptiste
    Khemissa-Akouz, Faiza
    Pere-Verge, Denis
    Delbaldo, Catherine
    Assenat, Eric
    Chauffert, Bruno
    Michel, Pierre
    Montoto-Grillot, Christine
    Ducreux, Michel
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) : 1817 - 1825
  • [6] Hydrophilic hydromer-coated polyurethane stents versus uncoated stents in malignant biliary obstruction: a randomized trial
    Costamagna, G
    Mutignani, M
    Rotondano, G
    Cipolletta, L
    Ghezzo, L
    Foco, A
    Zambelli, A
    [J]. GASTROINTESTINAL ENDOSCOPY, 2000, 51 (01) : 8 - 11
  • [7] RANDOMIZED TRIAL OF SELF-EXPANDING METAL STENTS VERSUS POLYETHYLENE STENTS FOR DISTAL MALIGNANT BILIARY OBSTRUCTION
    DAVIDS, PHP
    GROEN, AK
    RAUWS, EAJ
    TYTGAT, GNJ
    HUIBREGTSE, K
    [J]. LANCET, 1992, 340 (8834-5) : 1488 - 1492
  • [8] Prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin -: A multicenter randomized trial
    De Lédinghen, V
    Person, B
    Legoux, JL
    Le Sidaner, A
    Desaint, B
    Greff, M
    Moesch, C
    Grollier, G
    Ingrand, P
    Sautereau, D
    Beauchant, M
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (01) : 145 - 150
  • [9] Edge S.B., 2010, AJCC cancer staging manual, V649
  • [10] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247